로딩 중…
지수 로딩 중…
Upstream Bio, Inc.
UPB· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$6.42+1.74%
2026-08-03
Financials
Valuation Metrics
Upstream Bio, Inc.'s Market Cap is $349M. At end of 2025 it was $1.46B. Ranked #2922 of 3,111 in US market (top 94%), #1302 of 1,445 on NASDAQ (top 90%), #237 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $349M | US#2,922/3,111 Sec#237/269 |
| Revenue | $3M | US#2,958/3,111 Sec#195/269 |
| Net Income | $-157M | US—/3,111 Sec—/269 |
| Total Assets | $318M | US#2,891/3,111 Sec#205/269 |
| Net Assets | $304M | US#2,547/3,111 Sec#158/269 |
| Value | ||
| P/B | 1.15x | US#472/3,111 Sec#24/269 |
| P/S | 105.17x | US#2,915/3,111 Sec#183/269 |
| FCF Yield | -40.07% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -51.57% | US#2,751/3,111 Sec#176/269 |
| ROA | -49.29% | US#2,973/3,111 Sec#217/269 |
| Op. Margin | -5176.49% | US#2,955/3,111 Sec#191/269 |
| Revenue Growth | 82.69% | US#183/3,111 Sec#39/269 |
| Financial Health | ||
| Debt Ratio | 4.62% | US#43/3,111 Sec#16/269 |
| Total Debt | $1M | US#2,954/3,111 Sec#246/269 |
| FCF | $-140M | US#2,673/3,111 Sec#182/269 |
| Cash | $97M | US#2,238/3,111 Sec#181/269 |
| Current Ratio | 23.14x | US#104/3,111 Sec#22/269 |
| Performance | ||
| 1Y Return | -58.69% | US#3,027/3,111 Sec#256/269 |
| 1M Return | -14.51% | US#2,628/3,111 Sec#203/269 |
| From 52W High | -80.94% | US#3,082/3,111 Sec#267/269 |
| 1Y MDD | -81.84% | US#3,060/3,111 Sec#263/269 |
| Trading | ||
| Volume | 748,448 shares | US#2,454/3,111 Sec#237/269 |
| Trading Value | $5M | US#2,928/3,111 Sec#244/269 |
| Per Share | ||
| EPS | $-1.87 | US—/3,111 Sec—/269 |
| BPS | $7.02 | US#2,048/3,111 Sec#103/269 |